Medigard Ltd (ASX-MGZ) is an innovative international company originally founded in 1999 and listed on the ASX in February 2004.

Based in Gold Coast Australia, Medigard has been active in Research and Development, patenting and licensing.

This section is being updated

About Medigard

Board of Directors

Chris Bishop - Chairman

- B.Sc. (University of Auckland), Ph.D. (Experimental Pathology) (University of Queensland) -
Dr Bishop is Managing Director of Intellidesign Pty Ltd, an electronic design and manufacturing company that specialises in sophisticated electronic products including precision medical instruments and mobile wireless communication devices. After an academic career, Dr Bishop joined Cook Australia where he helped establish and manage a research and management group and manufacturing division in products that today are still widely exported internationally.

He chairs the Board’s Finance Committee and is a member of the Audit and Risk Committee and the Nomination and Remuneration Committee.

Ian Dixon - Executive Director

- B. Eng (Mech) (Swinburne University), MBA (Swinburne University), PhD (Monash University) -
Dr Dixon is a Managing Director and owner of Altnia Group, a biotechnology company with a portfolio of human therapeutic products and technologies. Dr Dixon is also a non-executive Director of Noxopharm (ASX-NOX), founder of Cynata Inc (now Cynata Therapeutics Ltd ASX-CYP) and founder of Exopharm. Dr Dixon is a co-inventor of a number of technologies and was the head of the Invetech Product Group, a leading medical device development business. Dr Dixon has direct experience in product innovation, technology commercialisation, partnering and capital raising.

Don Channer - Non-Executive Director

- B.Eng (University of Queensland) -
Mr. Channer’s career of over 50 years has been one of building many and varied successful enterprises. Commencing his working life in his own engineering consultancy practice, he expanded that business into international civil contracting with clients including Government and major corporations in Australia and S.E Asia. Mr Channer is a director of several private companies. Mr. Channer is a member of the Nomination and Remuneration Committee and the Finance Committee.

Craig Cameron - Non-Executive Director

-B.Eng (University of Queensland)-
Craig has almost 30 years’ CEO and board experience in a broad range of industries working in the USA, Canada, Japan, Australia, New Zealand and the UK running start-ups, turnarounds and mature businesses in IT services, nutraceuticals, information technology, communications, healthcare, green tech and clean technology industries. Craig has been a material shareholder and CEO of five companies in the USA, Australia, New Zealand and the UK.

Patricia Boero - Financial Officer

- B.Bus., FCA. -
Mrs Boero is the former Principal of successful accounting practice. A Chartered accountant for over 30 years, Mrs Boero has a variety of interests and continues to work with a clientele comprising a range of companies and industries. Mrs Boero has been a member and advisor to several Not for Profit organizations and is a director of several private companies.

Investor Centre

Medigard Limited (ASX-MGZ) is an Australian listed life sciences company with a history of product innovation and commercialisation.

Company Overview

Medigard presently has 135,300,327 ordinary shares on issue.

Medigard Limited has issued a further 80,000,000 unlisted options to Dr. Ian Dixon as part of his remuneration as Executive Director.

Future Directions

At its core, Medigard has sought to serve patients and health professionals with safe and efficacious products that are cost-effective and innovative.

New opportunities being investigated by the company will be synergistic and logical extensions of the core values of the company and push into value-add products and/or services.



Executive Director